ELND005 in Patients With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OPKO Health, Inc.; Transition Therapeutics Ireland Limited
• Collaborator: Transition Therapeutics
• Treatments: Inositol

Criteria

Inclusion Criteria:

• Diagnosis of probable AD

• Age 50 to 85 years, inclusive

• Mini-Mental Status Exam (MMSE) score of 16-26, inclusive

• Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD

• Fluency in English, French, or Spanish

• Stable doses of medications (cholinesterase inhibitors and memantine allowed)

• Caregiver is able to attend all study visits

Exclusion Criteria:

• Significant neurological disease other than AD

• Major psychiatric disorder

• Significant medical illness

• History of stroke or seizure

• History of a heart attack within the last 2 years

• Prior treatment with certain experimental medicines

• Presence of pacemakers or foreign metal objects in the eyes, skin, or body that would prevent patient from having MRI scan